Milgamma and Milgamma compositum use in the treatment of polyneuropathies of different genesis


Cite item

Full Text

Abstract

Currently the vitamins use in pharmacological doses is used not only in the treatment of many neurological syndromes, but also in the prevention of some diseases. Due to pluripotent mechanism of action, group B vitamins were successfully used in the treatment of neuropathies of various origins for the past 70 years. This article is devoted to drugs Milgamma and Milgamma compositum, which include vitamins B1, B6 and B12 (Milgamma) and benfotiamine in combination with pyridoxine (Milgamma compositum), as well as the role of these drugs in the treatment of diabetic and alcoholic polyneuropathy. The data suggest the use of Milgamma and Milgamma compositum as drugs of choice in neurological manifestations of metabolic disorders.

References

  1. Анисимова Е.И. Эффективность бенфотиамина в терапии алкогольной полиневропатии // Журнал неврологии и психиатрии им. С.С. Корсакова. 2001. Т. 12. № 101. С. 32-36.
  2. Анциферов М.Б., Волкова А.К. Диагностика и лечение диабетической дистальной полинейропатии у больных сахарным диабетом в амбулаторной практике // РМЖ. 2008. Т. 16. № 15.
  3. Балаболкин М.И. Применение препарата "Мильгамма" в комплексной терапии диабетической нейропатии: методические рекомендации. М., 2002.
  4. Верткин А.Л., Городецкий В.В. В чем преимущество бенфотиаминсодержащих препаратов мильгамма и бенфогамма в лечении диабетической полинейропатии // Фарматека. 2006. № 11. С. 83-89.
  5. Галиева О.Р., Джанашия П.Х., Мирина Е.Ю. Лечение диабетической нейропатии // РМЖ. 2005. № 10.
  6. Левин О.С. Применение бенфотиамина в лечении дисметаболических полинейропатий // Медицинский вестник. 2006. № 23-24 (366-367).
  7. Садеков Р.А., Данилов А.Б., Вейн А.М. Лечение диабетической полиневропатии препаратом мильгамма 100 // Журнал неврологии и психиатрии им. С.С. Корсакова. 1998. № 9. С. 30-32.
  8. Удовиченко О.В., Курцева Т.Г. Эффективность препарата Мильгамма в лечении болевого синдрома и трофических язв при диабетической полиневропатии // Клиническая диабетология. 1999. № 2. С. 32-34.
  9. Чернышева Т.Е. Витамины группы В в комплексной терапии диабетической нейропатии // Российские медицинские вести. 2001. № 4. С. 48-51.
  10. Babaei-Jadidi R, Karachalias N, Ahmed N, et al. Prevention of Incipient Diabetic Nephropathy by High-Dose Thiamine and Benfotiamine. Diabetes 2003;52:2110-19.
  11. Balakumar P, Sharma R, Singh M. Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacol Res 2008;58(5-6):356-63.
  12. Beltramo E, Berrone E, Tarallo S, et al. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol 2008;45(3):131-41.
  13. Bitsch R, Vortrag: Zur Biokinetik von Vitamin B1 (Thiamin) Praparaten. Symposium Interdisziplinare. Aspekte der peripheren und autonomen Neuropathien.
  14. Cameron NE, Gibson TM, Nangle MR, et al. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann N Y Acad Sci 2005;1043:784-92.
  15. Eckert M, Schejbal P. Therapy of neuropathies with a vitamin B combination. Symptomatic treatment of painful disease of the peripheral nervous system with a combination preparation of thiamine, pyridoxine and cyanocobalamin. Fortschr Med 1992;110(29):544-48.
  16. Gebhard KJ, Gridley DS, Stickney DR, et al. Enhancement of immune status by high levels of dietary vitamin B-6 without growth inhibition of human malignant melanoma in athymic nude mice. Nutr Cancer 1990;14(1):15-26.
  17. Green R. Is it time for vitamin B-12 fortification? What are the questions? Am J Clin Nutr 2009;89(2):712S-6S.
  18. Hammes HP, Du X, Edelstein D, et al. Ben fotiamine blocks three major pathways of hyperglycemic damage and prevents ex perimental diabetic retinopathy. Nat Med 2003;9:294-99.
  19. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy - a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005;43(2):71-77.
  20. Koltai MZ, Posa I, Winkler G, et al. The preventive effect of Benfotiamine on the development of cardiac autonomic neuropathy in dogs. 1997.
  21. Kretschmar C, Kaumeier S, Haase W. Medicamentous therapy of alcoholic polyneuropathy. Randomized double-blind study comparing 2 vitamin B preparations and a nucleotide preparation. Fortschr Med 1996;114:32:439-43.
  22. Li L, Cao D, Desmond R, et al. Cognitive performance and plasma levels of homocysteine, vitamin B12, folate and lipids in patients with Alzheimer disease. Dement Geriatr Cogn Disord 2008;26(4):384-90.
  23. Loew D. Pharmacokinetics of thiamine derivatives especially of benfothiamine. Int J of Clin Pharmacol And Therap 1996;34(2):47-50.
  24. Mooney S, Leuendorf JE, Hendrickson C, et al. Vitamin B6: a long known compound of surprising complexity. Molecules 2009;14(1):329-51.
  25. Oh SH, Witek RP, Bae SH, et al. Detection Of Transketolase In Bone Marrow-Derived Insulin Producing Cells: Benfotiamine Enhances Insulin Synthesis And Glucose Metabolism. Stem Cells Dev 2008 Apr 7. [Epub ahead of print].
  26. Peters TJ, Kotowicz J, et al. Treatment of alcoholic polyneuropathy with vitamin B complex: a randomised controlled trial. Alcohol Alcoholism 2006;41(6):636-42.
  27. Royer-Morrot MJ, Zhiri A, Paille F, et al. Plasma level concentrations after intramuscular and oral multiple dosage regimens in healthy men. Eur J Clin Pharmacol 1992;42(2):219-22.
  28. Schmid U, Stopper H, Heidland A, et al. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev 2008;24(5):371-77.
  29. Schmidt J. Wirksamkeit von Benfotiamin bei diabetischer Neuropathie - Breite Anwendungsbeobachtung unterstreicht Praxisbenefit. Der Kassenarzt, Heft 14/1 5. 2002;40-43.
  30. Scott K, Zeris S, Kothari MJ. Elevated B6 levels and peripheral neuropathies. Electromyogr Clin Neurophysiol 2008;48(5):219-23.
  31. Smith AD, Refsum H. Vitamin B-12 and cognition in the elderly. Am J Clin Nutr 2009;89(2):707S-11S.
  32. Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006;29(9):2064-71.
  33. Stirban A. Diabetes und Stoffwechsel 2005;(Suppl. 1):32-33.
  34. Stracke H, Gaus W, Achenbach U, et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008;116(10):600-05.
  35. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 2005;1(3):287-98.
  36. Vindedzis SA, Stanton KG, Sherriff JL, et al. Thiamine deficiency in diabetes - is diet relevant? Diab Vasc Dis Res 2008;5(3):215.
  37. Wiedney KD. Therapiewoche 1989;39:1445-49.
  38. Winkler G, Pal B, Nagybeganyi E, et al. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung 1999;49(3): 220-24.
  39. Woelk H, Lehrl S, Bitsch R, et al. Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAPI Study). Alcohol Alcoholism 1998;33(6):631-38.
  40. Zhiri A, Paille F, Royer RJ. Plasma thiamine concentrations after intramuscular and oral multiple dosage regimens in healthy men. Eur J Clin Pharmacol 1992;42(2):219-22.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies